Tastemaker Acquisition Corp.
TMKRW
NASDAQ Capital Market0.06
USD
+0.00
- -
CIK
0001821606
CUSIP
876545112
Return %
Stock
S&P500
1Y
-25.00
26.53
3Y
-93.94
76.60
5Y
-93.94
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David A. Pace
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 650 Fifth Avenue, New York City NY United States of America
- IPO Date
- Mar 1, 2021
- CIK
- 0001821606
- Website
- tastemakeracquisition.com
- Similar Companies
- Business
- Tastemaker Acquisition Corp. (NASDAQ: TMKR; TMKRW) operates as a blank check company whose sole purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, with a focus on the restaurant, hospitality and related technology and services sectors. The company offers no products or services beyond this acquisition mandate; its securities include shares of Class A common stock (TMKR), redeemable warrants exercisable for one share at $11.50 each (TMKRW) and units comprising one share and one-half warrant (TMKRU prior to separation). Founded in 2020 and headquartered in New York, New York, Tastemaker raised $276 million in its upsized initial public offering in January 2021, targeting enterprise values from $400 million to $1.5 billion or more in well-run companies within its sectors. In October 2022, Tastemaker entered a definitive business combination agreement with jewelry distributor Quality Gold Inc., valued at $989 million, under which the combined entity would have traded as Quality Gold Holdings Inc. (QGLD); the deal terminated mutually in June 2023 amid challenging market conditions for SPACs and high redemptions. In July 2023, Tastemaker rebranded as Priveterra Acquisition Corp. II, extended its completion deadline to January 2024, underwent a management change led by Oleg Grodnensky of Priveterra Capital with a shift toward life sciences focus, and adjourned shareholder votes multiple times to engage investors while facing Nasdaq compliance issues and trust value of approximately $29.8 million post-89.4% redemptions. As of mid-2023 SEC filings, no further business combination has materialized, leaving the company in ongoing search mode with limited operations and principal executive offices at 501 Madison Avenue, Floor 5, New York, NY 10019.